Sign Out
In Phase I multiple-dose studies, as observed with Sitagliptin there were no dose-related clinical adverse reactions with doses of up to 600 mg per day for periods of up to 10 days and 400 mg per day for periods of up to 28 days.
In the event of an overdose, the following supportive measures should be: Removal of unabsorbed material from the gastrointestinal tract; Clinical monitoring (including obtaining an electrocardiogram); Institute supportive therapy if required.
In clinical studies, Sitagliptin is modestly dialyzable, over a 3 to 4-hour hemodialysis session approximately 13.5% of it will be removed. If clinically relevant, prolonged hemodialysis sessions may be considered. Peritoneal dialysis is unidentified for Sitagliptin.
Continue with Google